CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 5.6%

CytomX Therapeutics Inc (NASDAQ:CTMX)’s share price rose 5.6% on Friday . The stock traded as high as $11.31 and last traded at $11.22. Approximately 239,944 shares traded hands during trading, a decline of 48% from the average daily volume of 461,258 shares. The stock had previously closed at $10.62.

CTMX has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. BidaskClub downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 9th. Barclays initiated coverage on shares of CytomX Therapeutics in a research note on Monday, March 11th. They set an “overweight” rating and a $16.00 price target for the company. HC Wainwright set a $34.00 price target on shares of CytomX Therapeutics and gave the company a “buy” rating in a research note on Tuesday, March 26th. Finally, ValuEngine raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. CytomX Therapeutics currently has an average rating of “Buy” and an average price target of $20.72.

The firm has a market capitalization of $508.39 million, a P/E ratio of -5.53 and a beta of 0.51. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.21 and a current ratio of 4.21. The stock has a 50 day moving average of $10.60.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.22. The company had revenue of $29.49 million during the quarter, compared to the consensus estimate of $13.59 million. CytomX Therapeutics had a negative net margin of 111.27% and a negative return on equity of 73.62%. Equities research analysts predict that CytomX Therapeutics Inc will post -2.13 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. Citigroup Inc. raised its stake in CytomX Therapeutics by 292.0% in the fourth quarter. Citigroup Inc. now owns 130,508 shares of the biotechnology company’s stock worth $1,971,000 after buying an additional 97,215 shares in the last quarter. Pictet Asset Management Ltd. grew its holdings in CytomX Therapeutics by 0.9% in the first quarter. Pictet Asset Management Ltd. now owns 611,356 shares of the biotechnology company’s stock worth $6,572,000 after purchasing an additional 5,670 shares during the last quarter. Victory Capital Management Inc. grew its holdings in CytomX Therapeutics by 79.9% in the first quarter. Victory Capital Management Inc. now owns 1,655,530 shares of the biotechnology company’s stock worth $17,797,000 after purchasing an additional 735,320 shares during the last quarter. State Board of Administration of Florida Retirement System grew its holdings in CytomX Therapeutics by 18.5% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 15,904 shares of the biotechnology company’s stock worth $240,000 after purchasing an additional 2,478 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. grew its holdings in CytomX Therapeutics by 25.0% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 490,988 shares of the biotechnology company’s stock worth $7,414,000 after purchasing an additional 98,261 shares during the last quarter. 81.83% of the stock is owned by institutional investors.

About CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Read More: What are municipal bonds?

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.